Q-omics provides the consensus-scored TPTE2 profile across patient tissues and cancer cell-line models. TPTE2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TPTE2 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, TPTE2 RNA expression shows 15,482 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, KICH, and THYM as cancer lineages where TPTE2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TPTE2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TPTE2 survival associations across molecular data types. TPTE2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TPTE2 RNA expression–survival associations across cancer types. High TPTE2 expression shows unfavorable associations in KIRC, UVM, KIRP and THCA, but favorable associations in UCS and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TPTE2 RNA expression.
This table summarizes TPTE2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for TPTE2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TPTE2 shows lower tumor expression in KICH and higher tumor expression in LUAD, HNSC, LUSC, LIHC and CHOL. The KICH box plot shows higher TPTE2 RNA expression in normal versus tumor tissue (log2 FC = −0.200, t-test p < 0.001).
This table shows molecular features associated with TPTE2 in patient tissues and cancer cell lines. In patient samples, TPTE2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TPTE2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
